On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint in ATTR cardiomyopathy. If you suffered a loss on your AstraZeneca investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Wainua, a gene-silencing drug for transthyretin-mediated amyloid cardiomyopathy, had been positioned as a key value driver toward AstraZeneca’s stated “$80 billion 2030 ambition.” The CARDIO-TTransform study was the largest trial in the ATTR cardiomyopathy population. On July 9, 2026, the Company disclosed that the trial did not meet its primary endpoint, and shares declined sharply on the news.
The investigation concerns whether AstraZeneca and certain of its officers may have made materially misleading statements or failed to adequately disclose information regarding the Wainua program prior to the July 9, 2026 announcement. On the Company’s Q2 2025 earnings call, held July 29, 2025, management described the CARDIO-TTransform readout as a highly anticipated catalyst for the ATTR cardiomyopathy population.
If you purchased AstraZeneca shares and suffered a loss, click here to have your losses reviewed. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report.
Frequently Asked Questions About the AZN Investigation
Q: How much did AZN stock drop? A: Shares had fallen more than 8% at open on July 9, 2026, after the Company disclosed that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint. Investors who purchased shares and suffered losses may be eligible to seek compensation.
Q: Who is eligible to participate in the AZN investigation? A: Investors who purchased AZN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What do AZN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my AZN shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AZN and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.
Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260713423442/en/
Media gallery
